The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS.
about
Spirodiketopiperazine-based CCR5 inhibitor which preserves CC-chemokine/CCR5 interactions and exerts potent activity against R5 human immunodeficiency virus type 1 in vitroRole for CCR5Delta32 protein in resistance to R5, R5X4, and X4 human immunodeficiency virus type 1 in primary CD4+ cellsGenetic variations in the receptor-ligand pair CCR5 and CCL3L1 are important determinants of susceptibility to Kawasaki diseaseNonhuman primate models for HIV/AIDS vaccine developmentRecent developments in human immunodeficiency virus-1 latency researchResistance to HIV InfectionEvaluating association and transmission of eight inflammatory genes with Viliuisk encephalomyelitis susceptibilityHuman immunodeficiency virus (HIV) entry inhibitors (CCR5 specific blockers) in development: are they the next novel therapies?SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivoMorphine enhances HIV-1SF162-mediated neuron death and delays recovery of injured neuritesTwo-stepping through time: mammals and virusesThe biology of CCR5 and CXCR4Global survey of genetic variation in CCR5, RANTES, and MIP-1alpha: impact on the epidemiology of the HIV-1 pandemic.Prevalence and clinical implications of epstein-barr virus infection in de novo diffuse large B-cell lymphoma in Western countries.Antiretroviral Activity Of a Novel Pyrimidyl-Di(Diazaspiroalkane) Derivative.Genome-wide scans for footprints of natural selection.Chemokine receptor CCR5 Delta 32 genetic analysis using multiple specimen types and the NucliSens Basic KitPathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo.HIV's response to a CCR5 inhibitor: I'd rather tighten than switch!Role of exonic variation in chemokine receptor genes on AIDS: CCRL2 F167Y association with pneumocystis pneumonia.A strong signature of balancing selection in the 5' cis-regulatory region of CCR5.Modulating influence on HIV/AIDS by interacting RANTES gene variantsMaraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.HIV-1 infection and AIDS dementia are influenced by a mutant MCP-1 allele linked to increased monocyte infiltration of tissues and MCP-1 levels.Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5.Genetic influence of CXCR6 chemokine receptor alleles on PCP-mediated AIDS progression among African Americans.Gulliver's travels in HIVland.HIV chemotherapy.Effect of CCR5-Δ32 heterozygosity on HIV-1 susceptibility: a meta-analysis.Quantitation of human immunodeficiency virus type 1 DNA forms with the second template switch in peripheral blood cells predicts disease progression independently of plasma RNA loadMamu-A*01 allele-mediated attenuation of disease progression in simian-human immunodeficiency virus infection.Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture.Polymorphisms in the genes encoding chemokine receptor 5, interleukin-10, and monocyte chemoattractant protein 1 contribute to cytomegalovirus reactivation and disease after allogeneic stem cell transplantation.Association of chemokine receptor gene (CCR2-CCR5) haplotypes with acquisition and control of HIV-1 infection in Zambians.Human retroviruses after 20 years: a perspective from the past and prospects for their future control.Distribution of CCR5-Delta32, CCR5 promoter 59029 A/G, CCR2-64I and SDF1-3'A genetic polymorphisms in HIV-1 infected and uninfected patients in the west region of CameroonAnalysis of the mechanism by which the small-molecule CCR5 antagonists SCH-351125 and SCH-350581 inhibit human immunodeficiency virus type 1 entry.Chemokine receptors: emerging opportunities for new anti-HIV therapies.PSC-RANTES blocks R5 human immunodeficiency virus infection of Langerhans cells isolated from individuals with a variety of CCR5 diplotypes.Minidefensins and other antimicrobial peptides: candidate anti-HIV microbicides.
P2860
Q24563937-039E6254-47B3-4AE7-B13E-275F33DF160FQ24608200-15A47AF5-0CFA-4EA9-8CF7-E6245E12067DQ24624734-98C36418-22FD-427B-BD38-93B4777C5CEAQ26861148-D438FABB-7815-4EB3-8CE4-C86359A1DAB4Q27013114-5D5D8B2B-0D1C-48F6-AF6D-556860FF8B5CQ27473466-96886094-1F93-4F96-88A0-46F6540448B7Q28265363-109CC24E-D527-4221-8D4A-E3671A5D4B9FQ28283307-938E86B3-E1BB-4DC0-9649-C4C2170304BBQ28362194-3609D70E-7CAB-4347-A5D0-ABA1B3916835Q28539889-9A4CB784-659A-41E6-A2D6-AC68F90E27D9Q28709092-62353308-FEA0-4FF2-85F8-EBAFBE17DE05Q29012920-7EF5CFA6-5E86-4165-A0EB-5168E2570334Q30328141-AD53D7AC-B407-4943-BD34-11C4D0BF4B9EQ33583294-1B70F212-E58D-42CB-A9BD-18BE4F8E1A02Q33607822-DD580252-F24B-4ABE-AB64-A30101AB8376Q33743128-57A78108-317D-415C-A7A8-0888737C6C0AQ33999482-2D99088F-E53D-4B49-81F4-4C8FBFE76152Q34007084-C458B8A8-FB37-4A9E-B6F0-5A09C61BD357Q34010925-33E20768-BCC0-4716-ABC7-C1B15226FAB0Q34064248-B5AF90CE-D1AA-4023-9C28-6D9CBDA5EE3DQ34075062-6C927822-8325-4750-88D0-17583B42F404Q34098634-4242EBE4-E76C-4542-B80E-A2B7C4E7D29EQ34123595-7774E7AD-96CF-4BE3-8259-7BD027D61A22Q34161535-AB84845A-B4FE-4113-8E08-44064E7BF550Q34169244-14388716-04AA-40F6-B7AE-63197F699C7EQ34199154-BA0537E9-54AC-4E85-97A8-BBDE76D703D9Q34223055-76106AB2-9494-4C5C-AE97-FCF2649D7199Q34223088-CC225BD1-FC8D-4736-83DD-37E62F8D3764Q34230435-21F3B119-841E-4B95-B297-CC758C2F1038Q34348055-089BB0A4-85CE-4F40-B14C-86FCEAD2D191Q34353799-23FD143F-5894-47A1-9DC9-214B4C82FCB7Q34670354-96D38DD1-22CE-4F26-9711-BBE42385FE5EQ34680855-66ACC7BF-4107-4169-85F7-D9F4B262B3BBQ34785274-48240FE4-260B-4F89-8C1E-56642C20478CQ34792498-6C88413E-E512-4F05-A1DB-117C24885E25Q34860765-5FCB191A-852B-4D4B-A65E-97F27AFC7797Q34975941-6226FBD1-E0D8-4A70-AA35-1F6D0F6D5D81Q35050395-77D59AEA-DAB4-4799-970E-7BE914D6C5A1Q35122309-D64D386F-6C2C-40DB-83A2-02C4F36174FAQ35143890-C888B0F8-D35B-4555-8D1B-6FCF05462583
P2860
The effect of genetic variation in chemokines and their receptors on HIV transmission and progression to AIDS.
description
2000 nî lūn-bûn
@nan
2000 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
The effect of genetic variatio ...... ssion and progression to AIDS.
@ast
The effect of genetic variatio ...... ssion and progression to AIDS.
@en
The effect of genetic variatio ...... ssion and progression to AIDS.
@nl
type
label
The effect of genetic variatio ...... ssion and progression to AIDS.
@ast
The effect of genetic variatio ...... ssion and progression to AIDS.
@en
The effect of genetic variatio ...... ssion and progression to AIDS.
@nl
prefLabel
The effect of genetic variatio ...... ssion and progression to AIDS.
@ast
The effect of genetic variatio ...... ssion and progression to AIDS.
@en
The effect of genetic variatio ...... ssion and progression to AIDS.
@nl
P1476
The effect of genetic variatio ...... ssion and progression to AIDS.
@en
P2093
P304
P356
10.1034/J.1600-065X.2000.17710.X
P577
2000-10-01T00:00:00Z